Q3 2017 Earnings Estimate for Ra Pharmctl Inc Issued By SunTrust Banks (NASDAQ:RARX)
Ra Pharmctl Inc (NASDAQ:RARX) – SunTrust Banks decreased their Q3 2017 earnings estimates for Ra Pharmctl in a research note issued to investors on Wednesday. SunTrust Banks analyst Y. Suneja now anticipates that the company will earn ($0.74) per share for the quarter, down from their previous forecast of ($0.52). SunTrust Banks also issued estimates for Ra Pharmctl’s Q4 2017 earnings at ($0.82) EPS, FY2017 earnings at ($2.63) EPS, FY2018 earnings at ($2.75) EPS and FY2019 earnings at ($3.00) EPS.
Ra Pharmctl (NASDAQ:RARX) last posted its earnings results on Wednesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by $0.06.
Other analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Ra Pharmctl from a “buy” rating to a “hold” rating in a research note on Thursday, May 25th. Jefferies Group LLC reiterated a “buy” rating and issued a $25.00 target price on shares of Ra Pharmctl in a research note on Friday, July 14th. Finally, Credit Suisse Group reiterated an “outperform” rating and issued a $19.00 target price on shares of Ra Pharmctl in a research note on Tuesday, April 18th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Ra Pharmctl currently has an average rating of “Buy” and a consensus price target of $27.00.
Shares of Ra Pharmctl (NASDAQ:RARX) opened at 13.73 on Monday. The firm’s market capitalization is $310.42 million. The firm has a 50-day moving average of $16.29 and a 200 day moving average of $20.32. Ra Pharmctl has a 12-month low of $12.05 and a 12-month high of $27.84.
In other news, major shareholder Bioventures Ltd Novartis sold 56,420 shares of the company’s stock in a transaction on Monday, June 19th. The shares were sold at an average price of $21.29, for a total value of $1,201,181.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders sold 208,880 shares of company stock valued at $4,946,431. Company insiders own 14.50% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. TIAA CREF Investment Management LLC raised its position in Ra Pharmctl by 97.0% in the first quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock valued at $167,000 after buying an additional 3,859 shares during the last quarter. American International Group Inc. bought a new position in Ra Pharmctl during the first quarter valued at $102,000. Geode Capital Management LLC raised its position in Ra Pharmctl by 8.5% in the first quarter. Geode Capital Management LLC now owns 70,863 shares of the company’s stock valued at $1,508,000 after buying an additional 5,522 shares during the last quarter. Wells Fargo & Company MN raised its position in Ra Pharmctl by 151.8% in the first quarter. Wells Fargo & Company MN now owns 9,455 shares of the company’s stock valued at $202,000 after buying an additional 5,700 shares during the last quarter. Finally, New York State Common Retirement Fund raised its position in Ra Pharmctl by 87.8% in the second quarter. New York State Common Retirement Fund now owns 13,900 shares of the company’s stock valued at $260,000 after buying an additional 6,499 shares during the last quarter. Institutional investors own 62.40% of the company’s stock.
Ra Pharmctl Company Profile
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with MarketBeat.com's FREE daily email newsletter.